This site is intended for health professionals only

At the heart of general practice since 1960

Pregnant women ‘more likely to discontinue epilepsy drugs’

Women with epilepsy need to be counselled on the risks of stopping anti-epilepsy drugs in pregnancy because many are still discontinuing treatment, a UK study has found.

The study

Only limited evidence is available about the discontinuation rates of anti-epilepsy drugs during pregnancy. UK researchers analysed prescribing trends for anti-epilepsy drugs from 1994 to 2009, based on primary care data for 174,055 pregnancies and anti-epilepsy drug use by 745 women with epilepsy and 54 with bipolar disorder.

The findings

Prescribing of newer anti-epilepsy drugs in pregnancy has steadily increased and lamotrigine has been the most popular anti-epilepsy drug prescribed in pregnancy since 2004, whereas use of carbamazepine and sodium valproate has declined. Pregnancy was linked to discontinuation of anti-epilepsy drugs, with discontinuation rates twice as high in women with epilepsy and three times higher for women with bipolar disorder compared with non-pregnant women using anti-epilepsy medications. 

What does it mean for GPs?

The authors recommend the risks and benefits of anti-epilepsy medications are explained to women - ideally prior to pregnancy - to allow them to make an informed decision on whether to continue treatment in pregnancy. They concluded: ‘Pregnancy is a strong determinant for the discontinuation of anti-epilepsy drug prescribing particularly for women with bipolar disorder.’

Expert comment

Dr Henry Smithson, a GP in Sheffield and the founding chair of the GP Society for Epilepsy, said: ‘There is good evidence from work in the UK and Ireland about the relative safety of anti-epileptic drugs in pregnancy. So the advice is to not change anything until you have received a specialist opinion when a women [with epilepsy] become pregnant, although that’s easier said than done. Pre-conception advice is also important. ‘

PLOS Medicine 2012; 157: 865-877

Have your say